Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA.
Intrastrand cross-links represent the majority of modifications in DNA resulting from interaction with the cancer chemotherapeutic drug cis-diamminedichloroplatinum(II) (cis-DDP). These adducts were recently characterized although several discrepancies remained to be resolved. In these studies, [3H]-cis-dichloro(ethylenediamine)platinum(II) (cis-DEP) was used because of the convenience of the radiolabel; this analogue produces adducts at identical sites in DNA as cis-DDP. Both drugs platinate the following sequences in DNA: GG, 65%; AG, 25%; GNG, 6%. The adduct at AG sequences invariably has adenine on the 5'-terminus of the dimer. The present enzyme digestion protocol included P1 nuclease, which produced complete digestion rather than as previously reported. The frequency of platination at GG was too high to be explained by an initial monofunctional platination at any guanine. However, direct bifunctional attack preferentially at GG was obviated because monofunctional adducts could be trapped with thiourea at short time periods. After short incubations, with cis-DEP and removal of unreacted drug, the monofunctional adducts slowly rearranged to bifunctional adducts. It is suggested that this evolution of adducts may result from the drug "walking" along the double helix, a phenomenon that does not appear to occur in single-stranded DNA.
D000818:Animals; D002417:Cattle; D002851:Chromatography, High Pressure Liquid; D002945:Cisplatin; D004247:DNA; D003850:Deoxyribonuclease I / Q000378:metabolism; D008297:Male; D010179:Pancreas / Q000201:enzymology; D012474:Salmon; D013737:Testis; D014316:Tritium
D014316:Tritium; D004247:DNA; D003850:Deoxyribonuclease I; D002945:Cisplatin